Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis

Visceral leishmaniasis is the most severe form of leishmaniases affecting millions of people worldwide often resulting in death despite optimal therapy. Thus, there is an urgent need for the development of effective anti-infective vaccine(s). In the present study, we evaluated the prophylactic value...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2012-07, Vol.30 (34), p.5086-5093
Hauptverfasser: Agallou, Maria, Smirlis, Despina, Soteriadou, Ketty P, Karagouni, Evdokia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 5093
container_issue 34
container_start_page 5086
container_title Vaccine
container_volume 30
creator Agallou, Maria
Smirlis, Despina
Soteriadou, Ketty P
Karagouni, Evdokia
description Visceral leishmaniasis is the most severe form of leishmaniases affecting millions of people worldwide often resulting in death despite optimal therapy. Thus, there is an urgent need for the development of effective anti-infective vaccine(s). In the present study, we evaluated the prophylactic value of bone marrow-derived dendritic cells (BM-DCs) pulsed with the Leishmania (L.) infantum histone H1. We developed fully mature BM-DCs characterized by enhanced capacity of IL-12 production after ex vivo pulsing with GST-LeishH1. Intravenous administration of these BM-DCs in naive BALB/c mice resulted in antigen-specific spleenocyte proliferation and IgG1 isotype antibody production and conferred protection against experimental challenge with L. infantum independently of CpG oligonucleotides (ODNs) co-administration. Protection was associated with a pronounced enhancement of parasite-specific IFNγ-producing cells and reduction of cells producing IL-10, whereas IL-4 production was comparable in protected and non-protected mice. The polarization of immune responses to Th1 type was further confirmed by the elevation of parasite-specific IgG2a/IgG1 ratio in protected mice. The above data indicate the immunostimulatory capacity of Leishmania histone H1 and further support its exploitation as a candidate protein for vaccine development against leishmaniasis.
doi_str_mv 10.1016/j.vaccine.2012.05.075
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1348487112</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0264410X12008274</els_id><sourcerecordid>1348487112</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-f232f64522e045774ad77e9d1e095a508c4ebf28b88aebf96e769a99030e41a23</originalsourceid><addsrcrecordid>eNqNkkFv1DAQhS0EokvhJwA-ckkYO3bsXEBVBRRpJQ6liJvldSasl8TZ2smi_nuc7tIDFzjZh--9eZo3hLxkUDJg9dtdebDO-YAlB8ZLkCUo-YismFZVwSXTj8kKeC0KweD7GXmW0g4AZMWap-SMcwWi4WJFbr_du9jJj4H-8tOWrtGn7WCDt3Tr0zQGpFes2M99wpa2GNroJ--ow75P1I2hw5joPo4TunsTH-gwxxyMHnxyGG1P-wfL5NNz8qSz2ezF6T0nNx8_fL28KtZfPn2-vFgXTig1FR2veFcLyTmCkEoJ2yqFTcsQGmklaCdw03G90drmT1OjqhvbNFABCmZ5dU7eHH1zttsZ02SGJU_f24DjnAyrhBZaMfYfKHAhVM11nVF5RF0cU4rYmX30g413GTJLMWZnTsWYpRgD0uRisu7VacS8GbB9UP1pIgOvj0BnR2N_RJ_MzXV2kABMVByW0e-PBOatHTxGk5zH4LD1Me_etKP_Z4h3fzm43gfvbP8T7zDtxjmGXIlhJmWNuV7uZzkfxgE0V6L6DcaywLY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1024476286</pqid></control><display><type>article</type><title>Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Agallou, Maria ; Smirlis, Despina ; Soteriadou, Ketty P ; Karagouni, Evdokia</creator><creatorcontrib>Agallou, Maria ; Smirlis, Despina ; Soteriadou, Ketty P ; Karagouni, Evdokia</creatorcontrib><description>Visceral leishmaniasis is the most severe form of leishmaniases affecting millions of people worldwide often resulting in death despite optimal therapy. Thus, there is an urgent need for the development of effective anti-infective vaccine(s). In the present study, we evaluated the prophylactic value of bone marrow-derived dendritic cells (BM-DCs) pulsed with the Leishmania (L.) infantum histone H1. We developed fully mature BM-DCs characterized by enhanced capacity of IL-12 production after ex vivo pulsing with GST-LeishH1. Intravenous administration of these BM-DCs in naive BALB/c mice resulted in antigen-specific spleenocyte proliferation and IgG1 isotype antibody production and conferred protection against experimental challenge with L. infantum independently of CpG oligonucleotides (ODNs) co-administration. Protection was associated with a pronounced enhancement of parasite-specific IFNγ-producing cells and reduction of cells producing IL-10, whereas IL-4 production was comparable in protected and non-protected mice. The polarization of immune responses to Th1 type was further confirmed by the elevation of parasite-specific IgG2a/IgG1 ratio in protected mice. The above data indicate the immunostimulatory capacity of Leishmania histone H1 and further support its exploitation as a candidate protein for vaccine development against leishmaniasis.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2012.05.075</identifier><identifier>PMID: 22704924</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Allergy and Immunology ; Animals ; Antibodies, Protozoan - blood ; Antibodies, Protozoan - immunology ; Antibody Formation ; Antigens, Protozoan - immunology ; Bone Marrow Cells - cytology ; Cell Proliferation ; CpG ODNs ; DCs-based vaccine ; death ; dendritic cells ; Dendritic Cells - immunology ; Female ; Histone H1 ; histones ; Histones - administration &amp; dosage ; Histones - immunology ; IFNγ ; IL-10 ; IL-12 ; Immunity, Cellular ; immunoglobulin G ; Immunoglobulin G - blood ; Injections, Intravenous ; Interferon-gamma - immunology ; interleukin-10 ; Interleukin-10 - immunology ; interleukin-12 ; Interleukin-12 - immunology ; interleukin-4 ; Interleukin-4 - immunology ; intravenous injection ; Leishmania ; Leishmania infantum ; Leishmania infantum - immunology ; Leishmania infantum - pathogenicity ; Leishmaniasis Vaccines - administration &amp; dosage ; Leishmaniasis Vaccines - immunology ; Leishmaniasis, Visceral - immunology ; Leishmaniasis, Visceral - parasitology ; Leishmaniasis, Visceral - prevention &amp; control ; Mice ; Mice, Inbred BALB C ; Murine visceral leishmaniasis ; oligodeoxyribonucleotides ; Oligonucleotides - immunology ; people ; Spleen - immunology ; Spleen - parasitology ; vaccination ; vaccine development ; vaccines ; visceral leishmaniasis</subject><ispartof>Vaccine, 2012-07, Vol.30 (34), p.5086-5093</ispartof><rights>Elsevier Ltd</rights><rights>2012 Elsevier Ltd</rights><rights>Copyright © 2012 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-f232f64522e045774ad77e9d1e095a508c4ebf28b88aebf96e769a99030e41a23</citedby><cites>FETCH-LOGICAL-c477t-f232f64522e045774ad77e9d1e095a508c4ebf28b88aebf96e769a99030e41a23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.vaccine.2012.05.075$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976,64366</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22704924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Agallou, Maria</creatorcontrib><creatorcontrib>Smirlis, Despina</creatorcontrib><creatorcontrib>Soteriadou, Ketty P</creatorcontrib><creatorcontrib>Karagouni, Evdokia</creatorcontrib><title>Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Visceral leishmaniasis is the most severe form of leishmaniases affecting millions of people worldwide often resulting in death despite optimal therapy. Thus, there is an urgent need for the development of effective anti-infective vaccine(s). In the present study, we evaluated the prophylactic value of bone marrow-derived dendritic cells (BM-DCs) pulsed with the Leishmania (L.) infantum histone H1. We developed fully mature BM-DCs characterized by enhanced capacity of IL-12 production after ex vivo pulsing with GST-LeishH1. Intravenous administration of these BM-DCs in naive BALB/c mice resulted in antigen-specific spleenocyte proliferation and IgG1 isotype antibody production and conferred protection against experimental challenge with L. infantum independently of CpG oligonucleotides (ODNs) co-administration. Protection was associated with a pronounced enhancement of parasite-specific IFNγ-producing cells and reduction of cells producing IL-10, whereas IL-4 production was comparable in protected and non-protected mice. The polarization of immune responses to Th1 type was further confirmed by the elevation of parasite-specific IgG2a/IgG1 ratio in protected mice. The above data indicate the immunostimulatory capacity of Leishmania histone H1 and further support its exploitation as a candidate protein for vaccine development against leishmaniasis.</description><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Antibodies, Protozoan - blood</subject><subject>Antibodies, Protozoan - immunology</subject><subject>Antibody Formation</subject><subject>Antigens, Protozoan - immunology</subject><subject>Bone Marrow Cells - cytology</subject><subject>Cell Proliferation</subject><subject>CpG ODNs</subject><subject>DCs-based vaccine</subject><subject>death</subject><subject>dendritic cells</subject><subject>Dendritic Cells - immunology</subject><subject>Female</subject><subject>Histone H1</subject><subject>histones</subject><subject>Histones - administration &amp; dosage</subject><subject>Histones - immunology</subject><subject>IFNγ</subject><subject>IL-10</subject><subject>IL-12</subject><subject>Immunity, Cellular</subject><subject>immunoglobulin G</subject><subject>Immunoglobulin G - blood</subject><subject>Injections, Intravenous</subject><subject>Interferon-gamma - immunology</subject><subject>interleukin-10</subject><subject>Interleukin-10 - immunology</subject><subject>interleukin-12</subject><subject>Interleukin-12 - immunology</subject><subject>interleukin-4</subject><subject>Interleukin-4 - immunology</subject><subject>intravenous injection</subject><subject>Leishmania</subject><subject>Leishmania infantum</subject><subject>Leishmania infantum - immunology</subject><subject>Leishmania infantum - pathogenicity</subject><subject>Leishmaniasis Vaccines - administration &amp; dosage</subject><subject>Leishmaniasis Vaccines - immunology</subject><subject>Leishmaniasis, Visceral - immunology</subject><subject>Leishmaniasis, Visceral - parasitology</subject><subject>Leishmaniasis, Visceral - prevention &amp; control</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Murine visceral leishmaniasis</subject><subject>oligodeoxyribonucleotides</subject><subject>Oligonucleotides - immunology</subject><subject>people</subject><subject>Spleen - immunology</subject><subject>Spleen - parasitology</subject><subject>vaccination</subject><subject>vaccine development</subject><subject>vaccines</subject><subject>visceral leishmaniasis</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkkFv1DAQhS0EokvhJwA-ckkYO3bsXEBVBRRpJQ6liJvldSasl8TZ2smi_nuc7tIDFzjZh--9eZo3hLxkUDJg9dtdebDO-YAlB8ZLkCUo-YismFZVwSXTj8kKeC0KweD7GXmW0g4AZMWap-SMcwWi4WJFbr_du9jJj4H-8tOWrtGn7WCDt3Tr0zQGpFes2M99wpa2GNroJ--ow75P1I2hw5joPo4TunsTH-gwxxyMHnxyGG1P-wfL5NNz8qSz2ezF6T0nNx8_fL28KtZfPn2-vFgXTig1FR2veFcLyTmCkEoJ2yqFTcsQGmklaCdw03G90drmT1OjqhvbNFABCmZ5dU7eHH1zttsZ02SGJU_f24DjnAyrhBZaMfYfKHAhVM11nVF5RF0cU4rYmX30g413GTJLMWZnTsWYpRgD0uRisu7VacS8GbB9UP1pIgOvj0BnR2N_RJ_MzXV2kABMVByW0e-PBOatHTxGk5zH4LD1Me_etKP_Z4h3fzm43gfvbP8T7zDtxjmGXIlhJmWNuV7uZzkfxgE0V6L6DcaywLY</recordid><startdate>20120720</startdate><enddate>20120720</enddate><creator>Agallou, Maria</creator><creator>Smirlis, Despina</creator><creator>Soteriadou, Ketty P</creator><creator>Karagouni, Evdokia</creator><general>Elsevier Ltd</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>C1K</scope><scope>F1W</scope><scope>H94</scope><scope>H95</scope><scope>H97</scope><scope>L.G</scope><scope>M7N</scope></search><sort><creationdate>20120720</creationdate><title>Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis</title><author>Agallou, Maria ; Smirlis, Despina ; Soteriadou, Ketty P ; Karagouni, Evdokia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-f232f64522e045774ad77e9d1e095a508c4ebf28b88aebf96e769a99030e41a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Antibodies, Protozoan - blood</topic><topic>Antibodies, Protozoan - immunology</topic><topic>Antibody Formation</topic><topic>Antigens, Protozoan - immunology</topic><topic>Bone Marrow Cells - cytology</topic><topic>Cell Proliferation</topic><topic>CpG ODNs</topic><topic>DCs-based vaccine</topic><topic>death</topic><topic>dendritic cells</topic><topic>Dendritic Cells - immunology</topic><topic>Female</topic><topic>Histone H1</topic><topic>histones</topic><topic>Histones - administration &amp; dosage</topic><topic>Histones - immunology</topic><topic>IFNγ</topic><topic>IL-10</topic><topic>IL-12</topic><topic>Immunity, Cellular</topic><topic>immunoglobulin G</topic><topic>Immunoglobulin G - blood</topic><topic>Injections, Intravenous</topic><topic>Interferon-gamma - immunology</topic><topic>interleukin-10</topic><topic>Interleukin-10 - immunology</topic><topic>interleukin-12</topic><topic>Interleukin-12 - immunology</topic><topic>interleukin-4</topic><topic>Interleukin-4 - immunology</topic><topic>intravenous injection</topic><topic>Leishmania</topic><topic>Leishmania infantum</topic><topic>Leishmania infantum - immunology</topic><topic>Leishmania infantum - pathogenicity</topic><topic>Leishmaniasis Vaccines - administration &amp; dosage</topic><topic>Leishmaniasis Vaccines - immunology</topic><topic>Leishmaniasis, Visceral - immunology</topic><topic>Leishmaniasis, Visceral - parasitology</topic><topic>Leishmaniasis, Visceral - prevention &amp; control</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Murine visceral leishmaniasis</topic><topic>oligodeoxyribonucleotides</topic><topic>Oligonucleotides - immunology</topic><topic>people</topic><topic>Spleen - immunology</topic><topic>Spleen - parasitology</topic><topic>vaccination</topic><topic>vaccine development</topic><topic>vaccines</topic><topic>visceral leishmaniasis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Agallou, Maria</creatorcontrib><creatorcontrib>Smirlis, Despina</creatorcontrib><creatorcontrib>Soteriadou, Ketty P</creatorcontrib><creatorcontrib>Karagouni, Evdokia</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) 1: Biological Sciences &amp; Living Resources</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) 3: Aquatic Pollution &amp; Environmental Quality</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Agallou, Maria</au><au>Smirlis, Despina</au><au>Soteriadou, Ketty P</au><au>Karagouni, Evdokia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2012-07-20</date><risdate>2012</risdate><volume>30</volume><issue>34</issue><spage>5086</spage><epage>5093</epage><pages>5086-5093</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Visceral leishmaniasis is the most severe form of leishmaniases affecting millions of people worldwide often resulting in death despite optimal therapy. Thus, there is an urgent need for the development of effective anti-infective vaccine(s). In the present study, we evaluated the prophylactic value of bone marrow-derived dendritic cells (BM-DCs) pulsed with the Leishmania (L.) infantum histone H1. We developed fully mature BM-DCs characterized by enhanced capacity of IL-12 production after ex vivo pulsing with GST-LeishH1. Intravenous administration of these BM-DCs in naive BALB/c mice resulted in antigen-specific spleenocyte proliferation and IgG1 isotype antibody production and conferred protection against experimental challenge with L. infantum independently of CpG oligonucleotides (ODNs) co-administration. Protection was associated with a pronounced enhancement of parasite-specific IFNγ-producing cells and reduction of cells producing IL-10, whereas IL-4 production was comparable in protected and non-protected mice. The polarization of immune responses to Th1 type was further confirmed by the elevation of parasite-specific IgG2a/IgG1 ratio in protected mice. The above data indicate the immunostimulatory capacity of Leishmania histone H1 and further support its exploitation as a candidate protein for vaccine development against leishmaniasis.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>22704924</pmid><doi>10.1016/j.vaccine.2012.05.075</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2012-07, Vol.30 (34), p.5086-5093
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_miscellaneous_1348487112
source MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland
subjects Allergy and Immunology
Animals
Antibodies, Protozoan - blood
Antibodies, Protozoan - immunology
Antibody Formation
Antigens, Protozoan - immunology
Bone Marrow Cells - cytology
Cell Proliferation
CpG ODNs
DCs-based vaccine
death
dendritic cells
Dendritic Cells - immunology
Female
Histone H1
histones
Histones - administration & dosage
Histones - immunology
IFNγ
IL-10
IL-12
Immunity, Cellular
immunoglobulin G
Immunoglobulin G - blood
Injections, Intravenous
Interferon-gamma - immunology
interleukin-10
Interleukin-10 - immunology
interleukin-12
Interleukin-12 - immunology
interleukin-4
Interleukin-4 - immunology
intravenous injection
Leishmania
Leishmania infantum
Leishmania infantum - immunology
Leishmania infantum - pathogenicity
Leishmaniasis Vaccines - administration & dosage
Leishmaniasis Vaccines - immunology
Leishmaniasis, Visceral - immunology
Leishmaniasis, Visceral - parasitology
Leishmaniasis, Visceral - prevention & control
Mice
Mice, Inbred BALB C
Murine visceral leishmaniasis
oligodeoxyribonucleotides
Oligonucleotides - immunology
people
Spleen - immunology
Spleen - parasitology
vaccination
vaccine development
vaccines
visceral leishmaniasis
title Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T04%3A57%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccination%20with%20Leishmania%20histone%20H1-pulsed%20dendritic%20cells%20confers%20protection%20in%20murine%20visceral%20leishmaniasis&rft.jtitle=Vaccine&rft.au=Agallou,%20Maria&rft.date=2012-07-20&rft.volume=30&rft.issue=34&rft.spage=5086&rft.epage=5093&rft.pages=5086-5093&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2012.05.075&rft_dat=%3Cproquest_cross%3E1348487112%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1024476286&rft_id=info:pmid/22704924&rft_els_id=1_s2_0_S0264410X12008274&rfr_iscdi=true